使用基孔肯雅减毒活疫苗后不良事件的监测，美国，2024年，以及2024年和2025年相关的公共卫生应对。

IF 7.8 2区医学 Q1 INFECTIOUS DISEASES

Eurosurveillance Pub Date : 2025-08-01 DOI:10.2807/1560-7917.ES.2025.30.32.2500543

Susan L Hills, Rebekah A Sutter, Elaine R Miller, Edwin J Asturias, Lin H Chen, Beth P Bell, Michael M McNeil, Jeffrey Rakickas, Melinda Wharton, Sarah Meyer, J Erin Staples

{"title":"使用基孔肯雅减毒活疫苗后不良事件的监测，美国，2024年，以及2024年和2025年相关的公共卫生应对。","authors":"Susan L Hills, Rebekah A Sutter, Elaine R Miller, Edwin J Asturias, Lin H Chen, Beth P Bell, Michael M McNeil, Jeffrey Rakickas, Melinda Wharton, Sarah Meyer, J Erin Staples","doi":"10.2807/1560-7917.ES.2025.30.32.2500543","DOIUrl":null,"url":null,"abstract":"A live attenuated chikungunya vaccine (IXCHIQ) received licensure in the United States (US) for ≥ 18-year-olds in November 2023. Post-licensure safety surveillance identified 28 adverse events in 2024 among US persons, including six neurological or cardiac serious adverse events (SAEs) in males ≥ 65 years. In early 2025, providers were alerted, a precaution for older persons was issued and vaccine guidance was updated. In May, following 11 additional SAEs reported outside the US, use in older persons was temporarily paused until 6 August 2025.","PeriodicalId":12161,"journal":{"name":"Eurosurveillance","volume":"30 32","pages":""},"PeriodicalIF":7.8000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12355908/pdf/","citationCount":"0","resultStr":"{\"title\":\"Surveillance for adverse events following use of live attenuated chikungunya vaccine, United States, 2024, and the associated public health response in 2024 and 2025.\",\"authors\":\"Susan L Hills, Rebekah A Sutter, Elaine R Miller, Edwin J Asturias, Lin H Chen, Beth P Bell, Michael M McNeil, Jeffrey Rakickas, Melinda Wharton, Sarah Meyer, J Erin Staples\",\"doi\":\"10.2807/1560-7917.ES.2025.30.32.2500543\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"A live attenuated chikungunya vaccine (IXCHIQ) received licensure in the United States (US) for ≥ 18-year-olds in November 2023. Post-licensure safety surveillance identified 28 adverse events in 2024 among US persons, including six neurological or cardiac serious adverse events (SAEs) in males ≥ 65 years. In early 2025, providers were alerted, a precaution for older persons was issued and vaccine guidance was updated. In May, following 11 additional SAEs reported outside the US, use in older persons was temporarily paused until 6 August 2025.\",\"PeriodicalId\":12161,\"journal\":{\"name\":\"Eurosurveillance\",\"volume\":\"30 32\",\"pages\":\"\"},\"PeriodicalIF\":7.8000,\"publicationDate\":\"2025-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12355908/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Eurosurveillance\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2807/1560-7917.ES.2025.30.32.2500543\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Eurosurveillance","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2807/1560-7917.ES.2025.30.32.2500543","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

摘要

一种基孔肯雅减毒活疫苗（IXCHIQ）于2023年11月在美国获得许可，用于≥ 的18岁儿童。许可后安全监测在2024年美国人中发现了28个不良事件，包括6个神经或心脏严重不良事件（sae），男性≥ 65岁。2025年初，向服务提供者发出了警报，发布了针对老年人的预防措施，并更新了疫苗指南。5月，在美国以外地区又报告了11例急性急性休克后，老年人的使用暂时停止，直到2025年8月6日 。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Surveillance for adverse events following use of live attenuated chikungunya vaccine, United States, 2024, and the associated public health response in 2024 and 2025.

A live attenuated chikungunya vaccine (IXCHIQ) received licensure in the United States (US) for ≥ 18-year-olds in November 2023. Post-licensure safety surveillance identified 28 adverse events in 2024 among US persons, including six neurological or cardiac serious adverse events (SAEs) in males ≥ 65 years. In early 2025, providers were alerted, a precaution for older persons was issued and vaccine guidance was updated. In May, following 11 additional SAEs reported outside the US, use in older persons was temporarily paused until 6 August 2025.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Eurosurveillance INFECTIOUS DISEASES-

CiteScore

32.70

自引率

2.10%

发文量

430

审稿时长

3-8 weeks

期刊介绍： Eurosurveillance is a European peer-reviewed journal focusing on the epidemiology, surveillance, prevention, and control of communicable diseases relevant to Europe.It is a weekly online journal, with 50 issues per year published on Thursdays. The journal includes short rapid communications, in-depth research articles, surveillance reports, reviews, and perspective papers. It excels in timely publication of authoritative papers on ongoing outbreaks or other public health events. Under special circumstances when current events need to be urgently communicated to readers for rapid public health action, e-alerts can be released outside of the regular publishing schedule. Additionally, topical compilations and special issues may be provided in PDF format.